Zynex

Zynex Liabilities

Delisted

The The Liabilities of Zynex (ZYXI) as of Nov 22, 2026 is 86.37 M USD. In the previous year, The Liabilities was 90.78 M USD — a change of -4.85% (lower).

Liabilities

86.37 MUSD

YoY

-4.85%

Last updated:

In 2024, Zynex's total liabilities amounted to 86.37 M USD, a -4.85% difference from the 90.78 M USD total liabilities in the previous year.

The Zynex Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
4.03 M USD
Jan 1, 2018
6.89 M USD
Jan 1, 2019
8.62 M USD
Jan 1, 2020
17.37 M USD
Jan 1, 2021
59.35 M USD
Jan 1, 2022
53.99 M USD
Jan 1, 2023
90.78 M USD
Jan 1, 2024
86.37 M USD
The Zynex Liabilities history
YEARLiabilitiesYoY
86.37 MUSD-4.85%
90.78 MUSD+68.13%
53.99 MUSD-9.03%
59.35 MUSD+241.71%
17.37 MUSD+101.39%
8.62 MUSD+25.24%
6.89 MUSD+71.00%
4.03 MUSD-48.98%
7.89 MUSD+1.62%
7.77 MUSD-7.33%
8.38 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Zynex's Liabilities

Zynex's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Zynex's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Zynex's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Zynex's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Zynex’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Zynex stock

The Liabilities of Zynex is 86.37 M USD in 2024.

The Liabilities of Zynex changed from 90.78 M USD to 86.37 M USD, representing a -4.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Zynex since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Zynex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zynex

All Key Metrics — Zynex